Leveraging the species barrier to advance cancer therapy
- PMID: 23800864
- DOI: 10.1038/ng.2683
Leveraging the species barrier to advance cancer therapy
Abstract
The discovery of new therapeutic targets and the personalization of treatments are two active areas of cancer research. New studies suggest that a 'co-clinical' approach may expedite both therapeutic target validation and risk stratification in patients with advanced prostate cancer.
Comment on
-
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.Nat Genet. 2013 Jul;45(7):747-55. doi: 10.1038/ng.2650. Epub 2013 Jun 2. Nat Genet. 2013. PMID: 23727860 Free PMC article.
-
Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.Nat Genet. 2013 Jul;45(7):739-746. doi: 10.1038/ng.2654. Epub 2013 Jun 2. Nat Genet. 2013. PMID: 23727861 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
